Internal Medicine, Infectious Disease · Baltimore, MD
NPI
1124080809
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
22 S Greene St
Baltimore, MD, 21201
Phone (410) 328-6979
Groups this clinician bills Medicare through
Medicare paid, 2024
$33K
475 services
Medicare patients, 2024
171
Average age 67
Drug cost, 2024
$4.8M
5,364 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mariam M Khambaty was code 99214 (office e&m - established), 205 times for 86 patients. In total Mariam M Khambaty billed 475 services in 14 codes, and Medicare paid $33K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 205 | 86 | $64.75 | $13K |
| 99213 Office E&M - Established | Facility | 85 | 51 | $49.93 | $4,244 |
| 99214 Office E&M - Established | Office | 81 | 48 | $94.75 | $7,675 |
| 99213 Office E&M - Established | Office | 36 | 27 | $67.85 | $2,442 |
By year: 2022 $29K for 392 services; 2023 $33K for 424 services; 2024 $33K for 475 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mariam M Khambaty prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 316 prescriptions and refills. In total Mariam M Khambaty wrote 5,364 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 316 | 316 | 45 | $1.2M |
| Atorvastatin Calcium Generic | 284 | 324 | 36 | $1,200 |
| Rosuvastatin Calcium Generic | 270 | 316 | 32 | $2,810 |
| Amlodipine Besylate Generic | 228 | 264 | 31 | $242 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 148 | 150 | 20 | $680K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 126 | 126 | 14 | $471K |
| Juluca Dolutegravir/Rilpivirine | 119 | 123 | 12 | $404K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 110 | 111 | 18 | $3,761 |
| Abacavir-Lamivudine Abacavir Sulfate/Lamivudine | 108 | 108 | 11 | $46K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 94 | 94 | 12 | $58K |
| Tamsulosin Hcl Generic | 93 | 97 | 12 | $885 |
| Dovato Dolutegravir Sodium/Lamivudine | 86 | 86 | 15 | $248K |
| Ventolin Hfa Albuterol Sulfate | 78 | 79 | 13 | $4,290 |
| Losartan Potassium Generic | 77 | 89 | 11 | $334 |
| Pifeltro Doravirine | 77 | 77 | Under 11 | $134K |
Brand drugs: 1,878 claims; generic drugs: 3,486 claims; opioid claims: 47.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Mariam M Khambaty were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.